The fitness cost of antibiotic resistance in streptococcus pneumoniae: Insight from the field

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Maher, M Cyrus ^a   Alemayehu, Wondu ^b   Lakew, Takele ^b   Gaynor, Bruce D ^a,c   Haug, Sara ^c   Cevallos, Vicky ^c   Keenan, Jeremy D ^a,c   Lietman, Thomas M ^a,c   Porco, Travis C ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ORBIS INTERNATIONAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; MEFA PROTEIN, STREPTOCOCCUS; MEFE PROTEIN, STREPTOCOCCUS PNEUMONIAE; MEMBRANE PROTEIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL SURVIVAL; BLINDING EYE DISEASE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CROSS RESISTANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MONITORING; DRUG USE; EYE DISEASE; FEMALE; HUMAN; INTRASPECIFIC COMPETITION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; NONHUMAN; OBSERVATIONAL STUDY; PREDICTION AND FORECASTING; PRESCHOOL CHILD; PRESCRIPTION; PROBALISTIC DISEASE TRANSMISSION MODEL; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; TRACHOMA; ALGORITHM; ANALYSIS OF VARIANCE; BIOLOGICAL MODEL; DRUG EFFECT; ETHIOPIA; GENETIC ASSOCIATION; GENETICS; MICROBIAL VIABILITY; MICROBIOLOGY; PNEUMOCOCCAL INFECTION; PREVALENCE; STATISTICS;

STREPTOCOCCUS PNEUMONIAE;

ALGORITHMS; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; ETHIOPIA; GENETIC ASSOCIATION STUDIES; HUMANS; MEMBRANE PROTEINS; MICROBIAL VIABILITY; MODELS, GENETIC; PNEUMOCOCCAL INFECTIONS; PREVALENCE; STREPTOCOCCUS PNEUMONIAE; TRACHOMA;

EID: 84855835106     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029407     Document Type: Article

References (32)

1. Advisory Committee On Immunization Practices (2000) Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and Reports 49 (RR-9): 1-35.
2. Mera R, Miller LA, Fritsche TR, Jones RN, (2008) Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist 14 (2): 101-107.
3. Hanage WP, Fraser C, Tang J, Connor TR, Corander J, (2009) Hyper-recombination, diversity, and antibiotic resistance in pneumococcus. Science 324 (5933): 1454-1457.
4. Appelbaum PC, (2002) Resistance among Streptococcus pneumoniae: Implications for drug selection. Clin Infect Dis 34 (12): 1613-1620.
5. Andersson DI, Hughes D, (2010) Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 8 (4): 260-271.
6. Rozen DE, McGee L, Levin BR, Klugman KP, (2007) Fitness costs of uoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 51 (2): 412-416.
7. Marcusson LL, Frimodt-Moller N, Hughes D, (2009) Interplay in the selection of uoroquinolone resistance and bacterial fitness. PLoS Pathog 5 (8): e1000541.
8. Levin BR, Perrot V, Walker N, (2000) Compensatory mutations, antibiotic resistance and the popu- lation genetics of adaptive evolution in bacteria. Genetics 154 (3): 985-997.
9. Trzcinski K, Thompson CM, Gilbey AM, Dowson CG, Lipsitch M, (2006) Incremental increase in fitness cost with increased beta-lactam resistance in pneumococci evaluated by competition in an infant rat nasal colonization model. J Infect Dis 193: 1296-1303.
10. Zhang Q, Sahin O, McDermott PF, Payot S, (2006) Fitness of antimicrobial-resistant Campylobacter and Salmonella. Microbes Infect 8 (7): 1972-1978.
11. McCallum N, Karauzum H, Getzmann R, Bischoff M, Majcherczyk P, et al. (2006) In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance. Antimicrob Agents Chemother 50 (7): 2352-2360.
12. Dagan R, Barkai G, Givon-Lavi N, Sharf AZ, Vardy D, et al. (2008) Seasonality of antibiotic-resistant streptococcus pneumoniae that causes acute otitis media: a clue for an antibiotic-restriction policy? J Infect Dis 197 (8): 1094-1102.
13. Kristinsson KG, (1997) Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci. Microb Drug Resist 3 (2): 117-123.
14. Riedel S, Beekmann SE, Heilmann KP, Richter SS, Garcia-de Lomas J, et al. (2007) Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Euro J Clin Microb Infect Dis 26 (7): 485-490.
15. Dagan R, Klugman K, (2008) Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 8 (12): 785-795.
16. Luciani F, Sisson SA, Jiang H, Francis AR, Tanaka MM, (2009) The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 106 (34): 14711-14715.
17. Haug S, Lakew T, Habtemariam G, Alemayehu W, Cevallos V, et al. (2010) The Decline of Pneu- mococcal Resistance after Cessation of Mass Antibiotic Distributions for Trachoma. Clin Infect Dis 51: 5-8.
18. Garcia-Rey C, Aguilar L, Baquero F, Casal J, Dal-Re R, (2002) Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Strep- tococcus pneumoniae. Journal of clinical microbiology 40 (1): 159.
19. Colijn C, Cohen T, Fraser C, Hanage W, Goldstein E, et al. (2010) What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae? J R Soc Interface 7 (47): 905-919.
20. Skalet AH, Cevallos V, Ayele B, Gebre T, Zhou Z, et al. (2010) Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial. PLoS Med 7 (12): e1000377.
21. Muluken Melese M, Chidambaram JD, Alemayehu W, Lee DC, Yi EH, et al. (2004) Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA 292 (6): 721-725.
22. Isozumi R, Ito Y, Ishida T, Osawa M, Hirai T, et al. (2007) Genotypes and related factors reecting macrolide resistance in pneumococcal pneumonia infections in Japan. J Clin Microbiol 45 (5): 1440-1446.
23. Spízek J, Rezanka T, (2004) Lincomycin, clindamycin and their applications. Appl Microbiol Biotech- nol 64 (4): 455-464.
24. Johnston NJ, De Azavedo JC, Kellner JD, Low DE, (1998) Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneu- moniae. Antimicrob Agents Chemother 42 (9): 2425-2426.
25. K Waites K, C Johnson C, B Gray B, K Edwards K, M Crain M, et al. (2000) Use of clindamycin disks To detect macrolide resistance mediated by ermB and mefE in Streptococcus pneumoniae isolates from adults and children. J Clin Microbiol 38 (5): 1731-1734.
26. Melegaro A, Choi Y, Pebody R, Gay N, (2007) Pneumococcal carriage in United Kingdom fami- lies: estimating serotype-specific transmission parameters from longitudinal data. Am J Epidemiol 166 (2): 228-235.
27. Hill PC, Townend J, Antonio M, Akisanya B, Ebruke C, et al. (2010) Transmission of Streptococcus pneumoniae in rural Gambian villages: a longitudinal study. Clin Infect Dis 50 (11): 1468-1476.
28. Melegaro A, Choi Y, George R, Edmunds WJ, Miller E, Gay N, (2010) Dynamic models of pneu- mococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. BMC Infect Dis 10: 90.
29. Sevillano D, Alou L, Aguilar L, Echevarría O, Giménez MJ, et al. (2006) Azithromycin iv pharma- codynamic parameters predicting Streptococcus pneumoniae killing in epithelial lining uid versus serum: an in vitro pharmacodynamic simulation. J Antimicrob Chemother 57 (6): 1128-1133.
30. Paris R, Confalonieri M, Dal Negro R, Ligia GP, Mos L, et al. (2008) Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days. J Chemother 20 (1): 77-86.
31. D'Ignazio J, Camere ME, Lewis DE, Jorgensen D, Breen JD, (2005) Novel, single-dose microsphere formulation of azithromycin versus 7-day levooxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. Antimicrob Agents Chemother 49 (10): 4035-4041.
32. Rossi F, Galassi M, Davies J, Theiler J, Gough B, et al. (2009) GNU Scientific Library Reference Manual Network Theory Ltd., v1.12 edition.